Standard therapy for advanced Prostate Cancer (PCa) consists of anti-androgens, which delays disease progression, but ultimately fails resulting in the incurable phase of the disease: Metastatic Castrate Resistant PCa (mCRPC). Targeting PCa cells before their progression to mCRPC would greatly improve the outcome. Understanding how Androgen-dependent PCa cells progress to independence and modify accordingly their transcriptional repertoire is the key to preventing mCRPC progression. We recently identified a novel axis of the Hippo pathway characterized by the sequential kinase cascade induced by androgen deprivation: AR down, leads to TLK1B up resulting in NEK1 activation which phosphorylates YAP1-Y407 leading to CRPC adaptation. We have now investigated additional details of this pathway with several different approaches. Firstly, we have overexpressed YAP1-WT or Y407F unphosphorylatable mutant in two cell lines (Hek293 and LNCaP) and have investigated their phenotypic and transcriptional changes, key among which was the adaptation of LNCaP cells expressing only the YAP1-WT to growth in androgen-depleted medium and progression to an EMT morphology, accompanied by transcriptional changes. Similarly, NT1 mouse PCa cells deficient in NEK1 displayed reduced motility concomitant with their reduced expression of N-Cadherin and Twist that we previously reported. Hek293 overexpressing YAP1-WT displayed greater induction of the apoptotic program in response to MMC, which is a feat dependent on the YAP1/p73 transcriptional programming, which further confirmed that YAP1-WT is significantly more stable and active as a co-activator than the Y407F mutant. Secondly, we investigated the importance of the NEK1>YAP1 axis in a GEMM generated by crossing TRAMP with NEK1-KO mice, and remarkably found that TRAMP mice haploinsufficient for NEK1 fail to progress to overt PRAD if castrated by 12 weeks. Finally, we have examined a collection of PCa biopsies by IHC using YAP1 and pYAP1-Y407 antisera and have found that the pYAP1- Y407 signal is low in samples of low-grade cancer but elevated in high gleason score (GS) specimens, whereas probing with the pan-YAP1 antiserum could not reveal this distinction so markedly. Importantly, we also found that J54, pharmacological inhibitor of the TLK1>NEK1>YAP1 nexus, leading to degradation of YAP1 can suppress the transcriptional reprogramming of LNCaP cells to Androgen-Independent (AI) growth and EMT progression even when YAP1-WT is overexpressed.